Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection

Figures & data

Table 1. Baseline demographic and clinical characteristics.

Characteristic	N = 59
Age, mean ± SD, year	55 ± 11.2
Gender, n (%)
Female	21 (35.6)
Male	38 (64.4)
Psoriasis duration, mean ± SD, year	14.5 ± 10.8
Psoriatic arthritis, n (%)	18 (30.5)
Duration, mean ± SD, year	7.4 ± 4.8
Comorbidities, n (%)
Hypertension	28 (47.5)
Dyslipidemia	22 (37.3)
Diabetes	17 (28.8)
Cardiopathy	15 (25.4)
Others^a	9 (15.3)
Prior conventional systemic treatment for psoriasis, n (%)	59 (100)
Cyclosporine	28 (47.5)
Phototherapy	23 (39.0)
Methotrexate	20 (33.9)
Acitretin	7 (11.9)
Fumarates	3 (5.1)
Prior biologic use	24 (40.7)
Adalimumab	16 (27.1)
Ustekinumab	12 (20.3)
Etanercept	5 (8.5)
Ixekizumab	2 (3.4)
Infliximab	1 (1.7)
Latent TBC infection	59 (100)
Anti-tuberculosis prophylaxis therapy, n (%)	49 (83.1)
Isoniazid	43 (72.9)
Isoniazid plus rifampicin	3 (5.1)
Rifampicin	3 (5.1)
Duration of prophylactic therapy, mean ± SD, weeks	23.1 ± 3.2

^aAutoimmune disease (n = 2), chronic obstructive pulmonary disease (3), and chronic gastritis, encephalopathy, renal failure, and peptic ulcer in 1 patient each.

SD: standard deviation; TBC: tuberculosis.